GlassScriptPhysician profile
Michele Ayans
NPI 1730340977
$1,361.05
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $203 · 2022: $500 · 2023: $434 · 2024: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $597 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $597.36 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $296.12 | 2022-2024 | |
| Abbvie INC. | $293.17 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $161.80 | 2021-2024 | Ilumya |
| Novartis Pharmaceuticals Corporation | $130.41 | 2021-2023 | |
| Incyte Corporation | $120.96 | 2022 | |
| Allergan, INC. | $76.44 | 2021-2022 | |
| Amgen INC. | $50.66 | 2024 | Otezla |
| Merz North America, INC. | $47.56 | 2021-2022 | |
| Biofrontera INC. | $46.27 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Ucb, INC. | $40.48 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $29.71 | 2022 | |
| Genzyme Corporation | $24.90 | 2022 | |
| Pfizer INC. | $22.55 | 2023 | |
| Vyne Pharmaceuticals INC. | $20.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Ayans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.